NASDAQ
LRMR

Larimar Therapeutics Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Larimar Therapeutics Inc Stock Price

Vitals

Today's Low:
$3.85
Today's High:
$4.08
Open Price:
$3.85
52W Low:
$2.58
52W High:
$6.85
Prev. Close:
$3.82
Volume:
76538

Company Statistics

Market Cap.:
$165.75 million
Book Value:
2.309
Revenue TTM:
$0
Operating Margin TTM:
0%
Gross Profit TTM:
$0
Profit Margin:
0%
Return on Assets TTM:
-25.93%
Return on Equity TTM:
-43.52%

Company Profile

Larimar Therapeutics Inc had its IPO on 2014-06-19 under the ticker symbol LRMR.

The company operates in the Healthcare sector and Biotechnology industry. Larimar Therapeutics Inc has a staff strength of 26 employees.

Stock update

Shares of Larimar Therapeutics Inc opened at $3.85 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $3.85 - $4.08, and closed at $4.01.

This is a +4.97% increase from the previous day's closing price.

A total volume of 76,538 shares were traded at the close of the day’s session.

In the last one week, shares of Larimar Therapeutics Inc have increased by +4.7%.

Larimar Therapeutics Inc's Key Ratios

Larimar Therapeutics Inc has a market cap of $165.75 million, indicating a price to book ratio of 1.6336 and a price to sales ratio of 0.

In the last 12-months Larimar Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-35900000. The EBITDA ratio measures Larimar Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Larimar Therapeutics Inc’s operating margin was 0% while its return on assets stood at -25.93% with a return of equity of -43.52%.

In Q2, Larimar Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Larimar Therapeutics Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-0.74 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Larimar Therapeutics Inc’s profitability.

Larimar Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -2.1441. Its price to sales ratio in the trailing 12-months stood at 0.

Larimar Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$111.72 million
Total Liabilities
$7.28 million
Operating Cash Flow
$0
Capital Expenditure
$0
Dividend Payout Ratio
0%

Larimar Therapeutics Inc ended 2024 with $111.72 million in total assets and $0 in total liabilities. Its intangible assets were valued at $111.72 million while shareholder equity stood at $99.93 million.

Larimar Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $7.28 million in other current liabilities, 43000.00 in common stock, $-166497000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $94.32 million and cash and short-term investments were $104.20 million. The company’s total short-term debt was $566,000 while long-term debt stood at $0.

Larimar Therapeutics Inc’s total current assets stands at $106.48 million while long-term investments were $0 and short-term investments were $9.88 million. Its net receivables were $0 compared to accounts payable of $2.34 million and inventory worth $0.

In 2024, Larimar Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Larimar Therapeutics Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$4.01
52-Week High
$6.85
52-Week Low
$2.58
Analyst Target Price
$11.88

Larimar Therapeutics Inc stock is currently trading at $4.01 per share. It touched a 52-week high of $6.85 and a 52-week low of $6.85. Analysts tracking the stock have a 12-month average target price of $11.88.

Its 50-day moving average was $3.67 and 200-day moving average was $4.3 The short ratio stood at 1.54 indicating a short percent outstanding of 0%.

Around 162.9% of the company’s stock are held by insiders while 8896.4% are held by institutions.

Frequently Asked Questions About Larimar Therapeutics Inc

The stock symbol (also called stock or share ticker) of Larimar Therapeutics Inc is LRMR

The IPO of Larimar Therapeutics Inc took place on 2014-06-19

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$12.05
-0.02
-0.17%
$117.2
-6.15
-4.99%
Seapeak LLC (SEAL-PB)
$24.36
0.06
+0.25%
Digjam Limited (DIGJAMLTD)
$101.6
0
0%
$116.15
-9.7
-7.71%
$4.53
0
0%
$11.48
0.38
+3.42%
$1870.8
7.9
+0.42%
$0.39
-0.01
-2.01%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 clinical trial for the treatment of Friedreich’s ataxia, a rare, progressive, and fatal genetic disease. The company is headquartered in Bala Cynwyd, Pennsylvania.

Address

Three Bala Plaza East, Bala Cynwyd, PA, United States, 19004